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Abstract
This study was conducted to develop a simple surrogate index comprised of routinely available
laboratory tests to reflect the histological fibrosis stage. Clinical characteristics and laboratory data
from 368 and 249 consecutive patients with chronic hepatitis C, a training cohort and a validation
cohort, respectively, were retrospectively evaluated. Platelet (Plt) count and albumin (Alb) level
contributed to the discrimination of the respective fibrosis stages. We derived the fi brosis index
(FI), FI = 8.0-0.01 x Plt (10 multiply 3/microliter) - Alb (g/dl), from a multiple regression model.
FI significantly correlated with the histological fibrosis stage in both the initial and validation
cohort at p=0.691 and p=0.661, respectively (Spearman’s rank correlation coefficient, p<0.0001).
The sensitivity and positive predictive value of FI at a cutoff value < 2.10 for predicting fibrosis
stage F0-1 were 66.8% and 78.8% in the initial cohort and 68.5% and 63.6% in the validation
cohort, respectively. Corresponding values of FI at a cutoff value >- 3.30 for the prediction of F4
were 67.7% and 75.0% in the initial cohort and 70.8% and 81.0% in the validation cohort. The
fibrosis index comprised of platelet count and albumin level reflected the histological fibrosis stage
in patients with chronic hepatitis C.
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hronic hepatitis C (CHC) is a progressive dis-
ease that is linked to cirrhosis and hepatocel-
lular carcinoma (HCC) development. The disease pro-
gression from mild chronic hepatitis to cirrhosis is 
evaluated by histological examination and expressed 
in terms of the stage of liver ﬁ brosis [1-5].  Knowing 
the exact stage of liver ﬁ brosis is crucial to making 
therapeutic decisions and assessing the prognosis of 
CHC patients.  Liver biopsy,  however,  is costly and 
presents a small risk for complications.  Histological 
examination,  therefore,  is rarely performed repeat-
edly,  even when the disease activity is severe and 
the progression of liver disease is highly suspected.
　　Despite the accuracy of histological examination 
in diagnosing chronic liver disease,  an evaluation of 
the disease progression based on biochemical and 
hematological tests is still indispensable as a daily 
practice for many patients with CHC.  Studies have 
been performed to establish noninvasive laboratory 
methods that can predict the severity of liver ﬁ brosis 
[6-13].  While these methods aim to predict either 
the presence or absence of signiﬁ cant ﬁ brosis and/or 
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This study was conducted to develop a simple surrogate index comprised of routinely available labo-
ratory tests to reﬂ ect the histological ﬁ brosis stage.  Clinical characteristics and laboratory data from 
368 and 249 consecutive patients with chronic hepatitis C,  a training cohort and a validation cohort, 
respectively,  were retrospectively evaluated.  Platelet (Plt) count and albumin (Alb) level contributed 
to the discrimination of the respective ﬁ brosis stages.  We derived the ﬁ brosis index (FI),  FI = 8.0 － 
0.01 × Plt (103/µl) － Alb (g/dl),  from a multiple regression model.  FI signiﬁ cantly correlated with 
the histological ﬁ brosis stage in both the initial and validation cohort at ρ=0.691 and ρ=0.661, 
respectively (Spearman’s rank correlation coeﬃ  cient, p<0.0001).  The sensitivity and positive predic-
tive value of FI at a cutoﬀ  value < 2.10 for predicting ﬁ brosis stage F0-1 were 66.8ｵ and 78.8ｵ in the 
initial cohort and 68.5ｵ and 63.6ｵ in the validation cohort,  respectively.  Corresponding values of FI 
at a cutoﬀ  value ≥ 3.30 for the prediction of F4 were 67.7ｵ and 75.0ｵ in the initial cohort and 70.8ｵ 
and 81.0ｵ in the validation cohort.  The ﬁ brosis index comprised of platelet count and albumin level 
reﬂ ected the histological ﬁ brosis stage in patients with chronic hepatitis C.
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cirrhosis in patients with chronic liver diseases, 
none can accurately or reliably reﬂ ect the respective 
ﬁ brosis stage from minimal chronic hepatitis to cir-
rhosis.  A better evaluation of the progression of 
liver disease is needed for use in the clinical practice 
of chronic liver diseases.  The aim of this study was 
to develop an index comprised of routinely available 
laboratory tests to reﬂ ect the ﬁ brosis stage and dis-
ease progression in patients with CHC.
Patients and Methods
　　Study Cohorts.　 Three hundred and sixty-eight 
consecutive patients with chronic hepatitis C virus 
(HCV) infection who underwent peritoneoscopic liver 
biopsy at Okayama University Hospital between 
January 1995 and December 2003 constituted the 
training cohort.  Two hundred and forty-nine patients 
with CHC who underwent liver biopsy at aﬃ  liated 
hospitals between January 2002 and December 2003 
constituted the validation cohort.  Patients with clini-
cally evident liver cirrhosis or decompensated liver 
disease (ascites,  jaundice,  variceal bleeding,  or 
encephalopathy) were excluded from the laparoscopic 
liver biopsy.  Patients with a concomitant infection of 
hepatitis B virus (HBV) and patients with other 
causes underlying liver disease were also excluded 
from the study.
　　CHC was diagnosed if alanine aminotransferase 
(ALT) was elevated greater than 36 IU/L within at 
least 6 months of the histological examination and a 
second-generation anti-HCV test (Abbott 
Laboratories,  Chicago,  IL,  USA) yielded positive 
results or HCV-ribonucleic acid (RNA) was present 
in serum as determined by either reverse transcrip-
tion-polymerase chain reaction (RT-PCR) or quantita-
tive assay (Amplicor HCV Monitor ; Roche 
Diagnostic Systems,  Branchburg,  NJ,  USA).
　　Laboratory examination and data 
collection.　 Clinical characteristics and laboratory 
data that were collected within 2 weeks before liver 
biopsy were retrieved from the liver biopsy data-
bases of the respective hospitals.  To identify the 
laboratory variables capable of predicting the respec-
tive ﬁ brosis stages,  we chose eleven clinical,  bio-
chemical,  and hematological variables for the analy-
sis : age,  gender,  white blood cell (WBC) count, 
platelet (Plt) count,  serum level of albumin (Alb), 
total bilirubin (T.Bil),  aspartate aminotransferase 
(AST),  ALT,  lactate dehydrogenase (LDH),  total 
cholesterol (T.Chol),  and prothrombin time (measured 
as a percentage of the daily internal control,  PT).
　　Liver biopsy and histological examina-
tion.　 Once informed consent was obtained from 
each patient,  peritoneoscopic liver biopsies were 
performed according to a standardized protocol. 
Biopsy specimens were ﬁ xed in formalin,  paraﬃ  n-
embedded,  and stained with hematoxylin-eosin,  azan 
stain,  and reticulin silver impregnation.
　　Specimens were reviewed by 2 experienced hepa-
topathologists who were blinded to the clinical char-
acteristics and laboratory results of the study sub-
jects.  The histology of liver biopsy specimens was 
evaluated for activity grade and ﬁ brosis stage accord-
ing to the criteria of Desmet et al. [3].
　　Statistical analysis.　 Unless otherwise stated, 
the descriptive statistics consisted of median values 
with the 1st and 3rd quartiles.  Spearman’s rank cor-
relation coeﬃ  cient was used to evaluate the signiﬁ -
cance of the correlation between histological ﬁ brosis 
stage and the continuous variables.  Categorical vari-
ables were compared using the chi-square test.
　　To select the predictive factors contributing to 
discrimination of the ﬁ brosis stage,  we performed 
univariate and multivariate logistic regression analy-
ses on the variables in F0-1 and F2,  F2 and F3, 
and F3 and F4 patients,  respectively.  Furthermore, 
a multiple regression analysis was used for studying 
the correlation between histological ﬁ brosis stage 
and the selected variables,  as well as for establishing 
a multiple regression model in which the ﬁ brosis 
stage was regarded as a continuous variable.  From 
the multiple regression model,  a simple index for 
predicting the ﬁ brosis stage was derived.  We then 
estimated the area under the receiver operating char-
acteristics (ROC) curve to evaluate the diagnostic 
ability of the established index.
　　A p value less than 0.05 was considered statisti-
cally signiﬁ cant.  Statistical analyses were performed 
using JMP computer software,  version 5.01J (SAS 
Institute Inc.,  Cary,  NC,  USA) and Stat View ver-
sion 5.0 (SAS Institute Inc.).
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Results
　　Patients’ clinical characteristics and 
laboratory data.　 Of the 368 patients in the train-
ing cohort,  184 (50.0ｵ),  85 (23.1ｵ),  68 (18.5ｵ), 
and 31 (8.4ｵ) were diagnosed with histological ﬁ bro-
sis stage F0-1,  F2,  F3,  and F4,  respectively (Table 
1).  Of the 11 demographical,  hematological,  and bio-
chemical variables studied,  9 variables,  age,  WBC, 
Plt,  Alb,  T.Bil,  AST,  ALT,  T.Chol,  and PT,  cor-
related with the ﬁ brosis stage (p<0.05 by Spearman’s 
rank correlation coeﬃ  cient).
　　Selection of variables and construction of a 
model for predicting ﬁ brosis stage.　 To select 
which variables could accurately discern the ﬁ brosis 
stage of each patient,  a logistic regression analysis 
was performed using the 11 variables in F0-1 and 
F2,  F2 and F3,  and F3 and F4 patients,  respec-
tively (Table 2).  Under this analysis,  we found that 
age,  WBC,  Plt,  Alb,  AST,  ALT,  T.Chol,  and PT 
could discriminate ﬁ brosis stage in F0-1 and F2 
patients ; Plt,  Alb,  and PT were signiﬁ cant vari-
ables capable of discriminating ﬁ brosis stage in F2 
and F3 patients ; and WBC,  Plt,  and Alb were the 
variables capable of discriminating the proper stage 
in F3 and F4 patients.  From these results,  Alb and 
Plt were identiﬁ ed as the predictive variables com-
mon to the discrimination of all categories of 
Table 1　　Clinical characteristics of chronic hepatitis C patients in the respective ﬁ brosis stages in the training cohort
Fibrosis stage
Variables F0-1 F2 F3 F4
No. of patients 184 85 68 31
Age* (years) 49 (37-58) 55 (49-62) 56 (50-62) 59 (49-63)
Gender (Male/Female) 110 / 74 51 / 34　 43 / 25　 19 / 12　
WBC* (x103 /µl) 5.5 (4.7-6.7) 4.7 (4.2-5.6) 5.5 (4.4-6.7) 4.8 (3.9-5.6)
Plt* (x103 /µl) 185 (160-220) 151 (132-184) 121 (101-145) 91 (79-100)
Alb* (g/dl) 4.3 (4.1-4.4) 4.1 (4.0-4.3) 4.0 (3.8-4.2) 3.6 (3.3-3.9)
T.Bil* (mg/dl) 0.67 (0.53-0.90) 0.75 (0.56-0.93) 0.83 (0.65-1.06) 0.98 (0.64-1.32)
AST* (IU/l) 36 (28-52) 59 (45-83) 65 (44-84) 68 (52-119)
ALT* (IU/l) 53 (34-88) 75 (48-117) 82 (51-127) 85 (56-128)
LDH (IU/l) 336 (293-390) 340 (394-395) 323 (277-387) 361 (283-437)
T.Chol* (mg/dl) 181 (160-212) 168 (152-191) 167 (154-200) 160 (136-182)
PT* (%) 100 (88-111) 95 (85-103) 87 (71-96) 77 (69-87)
Data are expressed as the median (the 1st and 3rd quartiles).
Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotrabsferase; LDH, lactate dehydrogenase; 
Plt, platelet; PT, prothrombin time; T.Bil, total bilirubin; T.Cho, total cholesterol; WBC, white blood cell.
*, Nine variables correlate with ﬁ brosis stage (p<0.05 by Spearman’s rank correlation coeﬃ  cient).
Table 2　　Univariate analysis of variables associated with discriminating between F0-1 and F2 (F0-1/F2),  F2 and F3 (F2/F3),  and F3 
and F4 (F3/F4) patients
F0-1 / F2 F2 / F3 F3 / F4
Variables OR 95%CI P value OR 95%CI P value OR 95%CI P value
Age (years) 1.06 (1.03-1.09) < 0.0001 1.01 (0.97-1.04) 0.798 1.03 (0.98-1.08) 0.292
Gender (Male) 1.01 (0.60-1.71) 0.973 1.15 (0.60-2.21) 0.683 0.92 (0.38-2.21) 0.853
WBC (x103/µl) 0.68 (0.55-0.84) 0.0003 1.24 (0.98-1.55) 0.071 0.70 (0.49-0.99) 0.042
Plt (x103/µl) 0.98 (0.98-0.99) < 0.0001 0.98 (0.97-0.99) < 0.0001 0.95 (0.93-0.98) < 0.0001
Alb (g/dl) 0.10 (0.04-0.30) < 0.0001 0.22 (0.07-0.76) 0.016 0.02 (0.00-0.11) < 0.0001
T.Bil (mg/dl) 1.05 (0.52-2.11) 0.889 3.06 (0.89-10.6) 0.077 1.17 (0.67-2.05) 0.589
AST (IU/l) 1.02 (1.01-1.03) < 0.0001 1.00 (1.00-1.01) 0.439 1.01 (1.00-1.02) 0.217
ALT (IU/l) 1.01 (1.00-1.01) 0.014 1.00 (1.00-1.01) 0.818 1.00 (0.99-1.01) 0.817
LDH (IU/l) 1.00 (1.00-1.00) 0.687 1.00 (0.99-1.01) 0.489 1.00 (1.00-1.01) 0.145
T.Chol (mg/dl) 0.99 (0.98-1.00) 0.003 1.01 (0.99-1.02) 0.310 0.99 (0.97-1.00) 0.059
PT (%) 0.98 (0.97-0.99) 0.005 0.98 (0.96-0.99) 0.016 0.98 (0.95-1.00) 0.080
OR, odds ratio; CI, conﬁ dence interval.
Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL, lactate dehydrogenase; Plt, platelet; 
Pt, prothrombin time; T.Bil, total bilirubin; T.Chol, total cholesterol; WBC, white blood cell.
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patients,  and multivariate logistic regression analysis 
revealed them to be independent variables as well 
(Table 3).
　　Step-wise multiple regression analysis,  which was 
used to formulate a suitable multivariable model for 
the correlation between laboratory variables and the 
ﬁ brosis stage,  revealed that Plt and Alb also inde-
pendently correlated with histological ﬁ brosis stage (F), 
R2=0.498.  The contribution of Plt and Alb to R2 was 
0.384 and 0.114,  respectively.  The ﬁ nal multiple 
regression model incorporating both Plt and Alb 
was :
　　F=8.28 － 0.01 × Plt (103/µl) － 1.08 × Alb (g/
dl).
　　Development of ﬁ brosis index (FI) and its 
diagnostic accuracy.　 Based on the multiple 
regression model described above,  we derived a 
novel index deﬁ ned by Plt and Alb,  called the ﬁ bro-
sis index (FI),  to reﬂ ect the ﬁ brosis stage :
　　FI = 8.0 － 0.01 × Plt (103/µl) － Alb (g/dl).
　　The FI distribution for patients in the respective 
ﬁ brosis stage is depicted in Fig.  1.  The median val-
ues for FI in F0-1,  F2,  F3,  and F4 patients were 
Table 3　　Multivariate analysis of platelet count (Plt) and serum albumin level (Alb) for discriminating between F0-1 and F2 (F0-1/F2), 
F2 and F3 (F2/F3),  and F3 and F4 (F3/F4) patients
F0-1 / F2 F2 / F3 F3 / F4
Variables OR 95%CI P value OR 95%CI P value OR 95%CI P value
Plt (x103/µl) 0.98 (0.98-0.99) < 0.0001 0.98 (0.97-0.99) < 0.0001 0.95 (0.92-0.98) 0.0005
Alb (g/dl) 0.14 (0.05-0.45) 0.0008 0.22 (0.06-0.82) 0.024 0.01 (0.00-0.10) < 0.0001
OR, odds ratio; CI, conﬁ dence interval.
Alb, albumin; Plt, platelet.
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Fig. 1　　Box plot of the ﬁ brosis index (FI) for each ﬁ brosis stage 
in the training cohort.  The top and bottom of boxes represent the 
25th and 75th percentiles,  respectively.  The entire box in each 
case thus represents the interquartiles range (IQR).  The upper 
error bar is the largest observation in the <75th percentile plus 1.5 
IQR,  and the lower error bar is the smallest observation in the 
>25th percentile minus 1.5 IQR.
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Fig. 2　　Receiver operating characteristic curves generated by the ﬁ brosis index (FI) used for discriminating between patients in ﬁ brosis 
stage (A) F0-1 and F2,  (B) F2 and F3,  and (C) F3 and F4 in the training cohort.
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1.88 (the 1st and 3rd quartiles,  1.44-2.23),  2.44 
(1.92-2.67),  2.74 (2.40-3.01),  and 3.60 (3.23-3.77), 
respectively.  FI signiﬁ cantly correlated with the his-
tological ﬁ brosis stage (Spearman’s rank correlation 
coeﬃ  cient,  ρ=0.691,  p<0.0001).
　　The diagnostic values of FI in the discrimination 
between F0-1 and F2,  F2 and F3,  and F3 and F4 
patients were evaluated using the area under the 
ROC curve (AUR) (Fig.  2).  The AUC for FI was 
0.741,  0.724,  and 0.914 in F0-1 and F2,  F2 and F3, 
and F3 and F4 patients,  respectively.  The cutoﬀ  
values obtained from the respective ROC curves 
were 2.10,  2.60,  and 3.30 in discriminating between 
F0-1 and F2,  between F2 and F3,  and between F3 
and F4 patients,  respectively.
　　For the same subjects in the initial cohort,  the 
AUC of FI for the discrimination between mild ﬁ bro-
sis (F0-1) and signiﬁ cant ﬁ brosis or cirrhosis (F2, 
F3,  F4),  and between non-cirrhosis (F0-1,  F2,  F3) 
and cirrhosis (F4) were 0.850 and 0.976,  respec-
tively (Fig.  3).  Table 4 illustrates 
the diagnostic accuracy of FI at dis-
criminating between mild ﬁ brosis 
(F0-1) and signiﬁ cant ﬁ brosis (F2, 
F3,  or F4),  and between non-cir-
rhosis (F0-1,  F2,  F3) and cirrhosis 
(F4).  Using a cutoﬀ  value of <2.10, 
FI had a sensitivity of 66.8ｵ,  a 
positive predictive value (PPV) of 
78.8ｵ with a speciﬁ city of 82.1ｵ, 
and a negative predictive value (NPV) 
of 71.2ｵ for the prediction of 
F0-1.  On the other hand,  at a cut-
oﬀ  value of 3.30 and more,  FI had a 
sensitivity of 67.7ｵ,  a PPV of 
75.0ｵ with a speciﬁ city of 97.9ｵ, 
and a NPV of 97.1ｵ for the predic-
tion of cirrhosis (F4).
　　Testing the validity of FI.　 FI was applied to 
the validation cohort comprised of 249 patients (F0-1, 
92 ; F2,  84 ; F3,  49 ; F4,  24) to test its accuracy 
and reproducibility.  The median of FI was 1.92 (the 
1st and 3rd quartiles,  1.59-2.26),  2.33 (1.87-2.79), 
2.78 (2.40-3.12),  and 3.61 (3.21-3.82) in the F0-1, 
F2,  F3,  and F4 patients of the validation cohort, 
respectively (Fig.  4).  FI correlated with histological 
ﬁ brosis stage in the validation cohort (Spearman’s 
rank correlation coeﬃ  cient,  ρ=0.661,  p<0.0001). 
Table 5 illustrates the diagnostic accuracy of FI in 
the validation cohort for discriminating mild ﬁ brosis 
(F0-1) from signiﬁ cant ﬁ brosis (F2,  F3,  or F4),  and 
cirrhosis (F4) from non-cirrhosis (F0-1,  F2,  or F3). 
At FI <2.10,  FI had a sensitivity of 68.5ｵ and PPV 
of 63.6ｵ with a speciﬁ city of 77.1ｵ,  and a NPV of 
80.7ｵ for predicting F0-1.  At FI ≥ 3.30,  FI had a 
sensitivity of 70.8ｵ and PPV of 81.0ｵ,  with a high 
speciﬁ city of 98.2ｵ,  and a NPV of 96.9ｵ for pre-
dicting F4.
Table 4　　Diagnostic accuracy of the ﬁ brosis index (FI) for the prediction of mild ﬁ brosis (F0-1) or liver cirrhosis (F4) in the training 
cohort
FI Interpretation Sensitivity Speciﬁ city PPV NPV LR Accuracy
Cutoﬀ  value (%) (%) (%) (%) (%)
< 2.1 F0-1 66.8 82.1 78.8 71.2 3.73 74.5
> 2.1 F2, F3, F4 82.1 66.8 71.2 78.8 2.48 74.5
< 3.3 F0-1, F2, F3 97.9 67.7 97.1 75.0 2.36 95.4
> 3.3 F4 67.7 97.9 75.0 97.1 32.61 95.4
PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.
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Fig. 3　　Receiver operating characteristic curves generated by the ﬁ brosis index (FI) 
for discriminating between (A) patients in the mild ﬁ brosis stage of F0-1 and patients 
in the signiﬁ cant ﬁ brosis stages of F2,  F3,  or F4,  and (B) non-cirrhotic F0-1,  F2,  or 
F3 patients and cirrhotic F4 patients.
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Discussion
　　The progression of chronic liver disease from 
mild chronic hepatitis to cirrhosis is expressed 
according to histological ﬁ brosis stage [1-5].  In this 
study,  we present a simple,  novel index called the 
ﬁ brosis index (FI) that uses platelet count and serum 
albumin level to reﬂ ect the disease progression 
associated with the development of ﬁ brosis stage in 
CHC patients. 
　　Several studies have described methods for 
predicting the presence or absence of signiﬁ cant 
ﬁ brosis and/or cirrhosis using noninvasive markers 
[6-13].  In a recent study,  Imberti-Bismut and the 
MULTIVIRC group reported that a combination of 5 
biochemical markers (Fibrotest) can be useful in 
discriminating between early and more advanced liver 
ﬁ brosis [10].  However,  the Fibrotest is somewhat 
diﬃ  cult to use in clinical practice,  since this assay 
utilizes less common biochemical markers such as 
ｸ2-macroglobulin,  haptoglobin,  and apolipoprotein 
A1,  and also requires use of a special computer 
program to perform the calculations.
　　Laboratory variables used for discriminant 
functions or scores must be more readily measurable, 
steady,  and cheap to obtain,  as well as contribute 
signiﬁ cantly toward the discrimination of patients 
with signiﬁ cant ﬁ brosis and/or liver cirrhosis.  In 
this study,  platelet count and albumin level were 
identiﬁ ed as independent predictive variables 
contributing to the discrimination of patients in the 
respective ﬁ brosis stages.  These 2 independent 
variables also correlated with histological ﬁ brosis 
stage in the multiple regression analysis.  It is well 
documented that Plt count decreases along with liver 
disease progression and adversely correlates with the 
ﬁ brosis stage [14‒16],  and a value for Plt count as 
a marker of liver ﬁ brosis has already been assigned 
[7-9,  11-13].  Serum albumin level also decreases 
in cases of liver cirrhosis and has been adopted into 
the Child-Turcotte classiﬁ cation [17] and Child-
Pugh classiﬁ cation [18],  both of which express the 
grade of liver cirrhosis.  Thus,  both Plt count and 
Alb level are easily measurable in daily practice for 
many CH-C patients,  and both meet the requirements 
described above.
　　Other variables such as age,  PT,  or T.Chol may 
play a role in the discrimination function and have 
been found useful in patients with signiﬁ cant ﬁ brosis 
or cirrhosis [7,  11,  12].  However,  compared to Plt 
and Alb,  these other variables correlate with the 
histological ﬁ brosis stage at a much smaller 
coeﬃ  cient of determination (R2) in the multiple 
Table 5　　Diagnostic accuracy of the ﬁ brosis index (FI) for the prediction of mild ﬁ brosis (F0-1) or liver cirrhosis (F4) in the validation 
cohort
FI Interpretation Sensitivity Speciﬁ city PPV NPV LR Accuracy
Cutoﬀ  value (%) (%) (%) (%) (%)
< 2.1 F0-1 68.5 77.1 63.6 80.7 2.99 73.9
> 2.1 F2, F3, F4 77.1 68.5 80.7 63.6 2.44 73.9
< 3.3 F0-1, F2, F3 98.2 70.8 96.9 81.0 3.37 95.6
> 3.3 F4 70.8 98.2 81.0 96.9 39.8 95.6
PPV,  positive predictive value ; NPV,  negative predictive value ; LR,  likelihood ratio.
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Fig. 4　　Box plot of the ﬁ brosis index (FI) for each ﬁ brosis stage 
in the validation cohort.  The top and bottom of boxes represent 
the 25th and 75th percentiles,  respectively.  The entire box thus 
represents the interquartiles range (IQR).  The upper error bar is 
the largest observation in the <75th percentile plus 1.5 IQR.  The 
lower error bar is the smallest observation in the >25th percentile 
minus 1.5 IQR.
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regression analysis in our cases.  On the other hand, 
since Wai suggested that 2 variables can be 
practically used in a prediction index [13],  we 
decided to construct a simple function using Plt and 
Alb because of their convenience of application in 
general practice.
　　Most of the noninvasive diagnosis methods 
reported previously have focused on predicting either 
the presence or absence of signiﬁ cant ﬁ brosis and/or 
cirrhosis.  For example,  the index of Forns [12], 
which aims at predicting the absence of signiﬁ cant 
ﬁ brosis,  can detect patients without signiﬁ cant 
ﬁ brosis (F0-F1) at a sensitivity of 51ｵ and PPV of 
96ｵ (speciﬁ city of 94ｵ,  NPV 41ｵ) at the lower 
cutoﬀ  value ; in patients with signiﬁ cant ﬁ brosis and/
or liver cirrhosis (F2-F4) there is a low sensitivity 
of 30ｵ and PPV of 66ｵ at the higher cutoﬀ  value. 
The Fibrotest of the MULTIVIR group predicts 
signiﬁ cant ﬁ brosis (F2-F4) at a sensitivity of 50ｵ 
and PPV of 79ｵ (speciﬁ city 91ｵ,  NPV of 73ｵ) at 
the cutoﬀ  value of 0.60 [19].  The index of Wai 
predicts signiﬁ cant ﬁ brosis and/or cirrhosis (Ishak 
score 3-6) with a sensitivity of 41ｵ and PPV of 88
ｵ (speciﬁ city 95ｵ,  NPV 64ｵ) at the cutoﬀ  value 
of 1.5,  and cirrhosis (Ishak score 5-6) with a 
sensitivity of 57ｵ and PPV of 57ｵ (speciﬁ city 93ｵ, 
NPV 93ｵ) at the cutoﬀ  value of 2.0 [13].  While 
these noninvasive tests are available for predicting 
either the presence or absence of signiﬁ cant ﬁ brosis 
and/or cirrhosis,  as pointed out elsewhere [20], 
they cannot truly distinguish between the respective 
histological ﬁ brosis stages.  On the other hand,  the 
purpose of our study was to adequately reﬂ ect each 
respective ﬁ brosis stage from mild ﬁ brosis (F0-1) to 
cirrhosis (F4).  FI was derived from the multiple 
regression model,  in which the correlation between 
histological ﬁ brosis stage and the selected variables 
of Plt and Alb were studied.  FI correlated with the 
histological ﬁ brosis stage,  and the values of FI 
approximately corresponded to the ﬁ brosis stage.  FI 
could discriminate between mild ﬁ brosis (F0-1) and 
signiﬁ cant ﬁ brosis (F2,  F3,  and F4) with an AUR of 
0.850,  a value comparable to that of Forns’ index 
[12],  the index of Wai [13],  or Fibrotest [19].  FI 
could also distinguish cirrhosis from non-cirrhosis 
with an AUR of 0.976,  which means that FI could 
reﬂ ect the respective ﬁ brosis stages from mild 
ﬁ brosis (F1) to cirrhosis (F4) with acceptable 
accuracy.
　　In previous reports,  the lack of ﬁ brosis or 
ﬁ brosis limited to the portal tract is associated with 
favorable outcome and sustained virological response 
to interferon therapy [21,  22].  Advanced liver 
ﬁ brosis has been revealed to be more likely to 
develop hepatocellular carcinoma [23,  24].  These 
ﬁ ndings show that the evaluation of histological 
ﬁ brosis stage is especially important in the 
management of patients with CHC.  However,  the 
histological examination is rarely performed repeat-
edly.  Therefore,  in general practice,  physicians may 
be able to use FI instead of histological examination 
to decide whether to initiate or continue interferon 
therapy and to assess the progression of liver disease 
and the risk of hepatocarcinogenesis in patients with 
CHC.  On the other hand,  since FI was generated 
from the data of HCV-related chronic liver disease, 
we do not yet know whether FI is suitable for the 
evaluation of the ﬁ brosis stage in HBV-related 
chronic liver disease.  To examine this issue,  other 
studies must be performed.
　　Since chronic hepatitis in the advanced stage 
sometimes shows transitional histological ﬁ ndings 
from mild to moderate chronic hepatitis,  moderate to 
severe chronic hepatitis,  and severe chronic hepatitis 
to liver cirrhosis,  even a pathological examination 
cannot always clearly discriminate between the 
various ﬁ brosis stages [25].  Discrimination analysis, 
therefore,  has a fundamental limitation in establish-
ing complete diﬀ erentiation of the continuous disease 
entities.  With these limitations under consideration, 
FI shows acceptable accuracy in the evaluation of 
CHC disease progression in connection with the 
development of histological ﬁ brosis stage.
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